<!DOCTYPE html>

<html lang="en">
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/cs.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" src="js/Common.js"></script>
    <script type="text/javascript" charset="utf-8">
		
		//delay = 500;
		ANIMATION = [
                 maskY('.bars'),
				 fade('.labels'),
				 fade('.dashes')

		   ];
		
	
	</script>

</head>

<body class="slide-4">

<div id="content">
<div class="collage"></div>

<header>
CASTLE: Lipid changes in treatment-naïve patients

</header>

<div class="logo"></div>

<section>

<article>
	<div class="chartwrap">
    	<div class="chartbk"></div>
        <div class="title">Mean fasting lipid levels at baseline and week 96<sup>3,4</sup></div>
    	<div class="bars"></div>
        <div class="labels"></div>
        <div class="dashes"></div>
    
    
    </div>


</article>

<aside>


<p class="bullet">Mean % changes in fasting TC, <br>non-HDL, and TG from baseline <br>at week 96 were significantly higher <br>in the KALETRA arm than the atazanavir/ritonavir arm (<em>P</em>&lt;0.0001).<sup>3</sup></p>
<p class="bullet">25% of patients receiving KALETRA<br>had total cholesterol <span class="symbol">≥</span>240 mg/dL<br>and 4% had triglycerides &gt;750 mg/dL at week 96, compared with 11% and &lt;1% for the atazanavir/ritonavir group.<sup>3</sup></p>
<p class="bullet">2% of atazanavir/ritonavir vs 9% of KALETRA patients initiated lipid-lowering therapy after the start of study therapy.<sup>3</sup></p>
<p class="pad1"><strong>Safety Considerations</strong></p>
<p id="pad2" class="bullet">Treatment with KALETRA has resulted<br>in large increases in concentrations<br>of total cholesterol and triglycerides.<br>Monitor lipids prior to therapy and<br>periodically thereafter.</p>
<p class="bullet">KALETRA is contraindicated with<br>lovastatin or simvastatin.</p>
<p class="bullet">Treat patients for lipid elevations<br>as clinically appropriate.</p>
</aside>


</section>

<div class="buttonwrap">
    <button onclick="makecall('PopupWithHeader',Array('cs-04-popup-01','Study Design','<table width=\'830px\'><tr align=\'center\'><td class=\'reference\'>CASTLE Study Design<sup>2,3</sup></td></tr></table>','90','625','10','0','830','500','1','0','1','0'));">Study Design</button>
    <button onclick="makecall('PopupWithHeader',Array('cs-04-popup-02','NCEP Guidelines','<table width=\'435px\'><tr align=\'center\'><td class=\'reference\'>NCEP Guidelines</td></tr></table>','230','625','10','0','435','260','1','0','1','0'));">NCEP Guidelines</button>
</div>

<footer>Please click buttons above for Indication and Important Safety Information about KALETRA.</footer>


</div>
</body>
</html>

